Bioassays & Bioanalytical Method Development Session Spotlight: Development and Validation of a Cell-Based Viral Neutralization Assay

Cell-based assay approaches for NAbs are extremely complicated; no two are exactly the same. The necessary procedures are made even more demanding in the design of vaccines, because in that circumstance you want to provoke an immune response. It is worth the time required to master these taxing skills in order to demonstrate the most effective means of viral inhibition and minimization of rate of spread.

We'll be examinnig this topic at the Bioassays and Bioanalytical Method Development Event next month.  For more information on this session and the rest of the event, download the agenda.  As a reader of this blog, when you register to join us this October 1-3 in Berkley, California and mention code XP1768BLOG, you'll save 15% off the standard rate!

Featured Session: Development and Validation of a Cell-Based Viral Neutralization Assay
Featured Speaker: Peter Day, PhD, Associate Scientist, Genentech
About the session: You can best demonstrate effective means of viral inhibition through creation of two distinct MOA pathways, thus minimizing the risk and spread rate of infection. It is worth the time necessary to reorient your assay and analytic design processes around this goal, as the new inhibition results are crucial in the engineering of both vaccines and therapeutic proteins.

• • Reinterpret immunoassay results in the context of seeking to provoke immune response
• • Plan the best molecular design methods for viral load suppression
• • Prepare for regulatory submission even when current guidelines are unclear

Share this article with your social network, just click below to share now!

Share |